#Health #Diagnostics
- MedTech
- Artificial Intelligence
- Deep Learning
- Medical device
- SaaS
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Health #Diagnostics
Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.
We are currently developing an AI solution for the early detection of the main liver cancer, hepatocellular carcinoma (HCC).
BACKGROUND
Echoliv a été fondée par : Jules Bayet, ingénieur en machine learning, diplômé de l’École Polytechnique ; Victor Neuillet, serial entrepreneur, diplômé de l’ESCP Business School ; Elsa Angelini, experte en machine learning appliquée à l’imagerie médicale avec un doctorat en imagerie biomédicale, professeure-associée à Télécom Paris, Imperial College London et Columbia.
DESCRIPTION OF PRODUCTS / SERVICES / TECHNOLOGY
Echoliv is involved in the diagnosis of early stage HCC. The objective is to concretely bring a gain in specificity and sensitivity in order to increase the number of diagnoses of sick patients and also to reduce positive tests on non-sick patients.
The Echoliv solution is an artificial intelligence-based medical technology for ultrasound. The algorithms analyse and process the images, and detect traces of HCC if present. Radiologists and X-ray manipulators acquire ultrasound videos as in standard practice and thus receive valuable decision support: the algorithm will provide multi-signal identification.
COLLABORATIONS / HIGHLIGHTS
The Echoliv solution will be based on an architecture and know-how developed and tested during academic research on the classification of liver pathology (and particularly HCC).
COLLABORATIONS SOUGHT
Echoliv is looking for hospital partners in order to acquire more data and test the solution directly in the hands of radiologists and hepatologists.
STRENGTHS:
Know-how in machine learning applied to liver ultrasound
INNOVATION ASSETS:
Development of an AI solution that supports ultrasound screening for the major liver cancer (hepatocellular carcinoma)
In same field